For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 70,095 | |||
| General and administrative | 15,215 | |||
| Total operating expenses | 85,310 | |||
| Operating loss | -85,310 | |||
| Interest and investment income, net | 5,530 | |||
| Interest expense | 0 | |||
| Other income, net | 1,243 | |||
| Total other income, net | 6,773 | |||
| Net loss | -78,537 | |||
| Basic EPS | -5.9 | |||
| Diluted EPS | -5.9 | |||
| Basic Average Shares | 13,317,116 | |||
| Diluted Average Shares | 13,317,116 | |||
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Corbus Pharmaceuticals Holdings, Inc. (CRBP)